Netscientific Share Discussion Threads

[howdlep] 04/8/2015 08:19

its proving very difficult to acquire stock. No wonder Liberum are currently bidding for 50k to fill orders.

200p not far away imo...

[hydrus] 04/8/2015 08:16

Surprisingly muted response

[themadstork] 04/8/2015 07:40

Indeed. Great to see the BoD implementing a better newsflow strategy.

[howdlep] 04/8/2015 07:18

Excellent news and with such a small free float, this will move very quickly on even small volume:-


ProAxsis launches first-in-class ProteaseTag test

RNS

RNS Number : 9521U

NetScientific PLC

04 August 2015



NetScientific plc



ProAxsis launches first-in-class ProteaseTagTM test for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease


London, UK - 4 August 2015 - NetScientific portfolio company, ProAxsis, a medical diagnostics spin-out from Queen's University Belfast, has officially launched its proprietary first-in-class ProteaseTag™ immunoassay kits to research labs and announces its first two customer orders, including a major pharma company.



ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. This test measures Neutrophil Elastase, a leading indicator of infection in patients with Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) and an important drug target. The rapid and easy-to-use tests incorporate patented ProteaseTags™; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags™ provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.



ProAxsis is one of NetScientific's five core portfolio companies that it highlighted at the time of its full year results in March. The biomedical and healthcare technology group began investing in the company in February 2014 to further develop and commercialise its range of novel medical diagnostic tests. Now, with the launch of its first-in-class immunoassay kit, ProAxsis will focus on building its academic and pharma customer base and developing other products for different indications.


David Gough, Chairman of ProAxsis, and Executive Director of NetScientific, said: "The launch of the first ProteaseTag™ immunoassay is a major milestone for ProAxsis. We believe there is a huge potential demand for the Neutrophil Elastase test that could significantly contribute to respiratory disease and infection research. ProteaseTags™ also have the benefit of being applicable to a wide pipeline of products targeting other diseases, such as cancer and cardiovascular disorders, allowing ProAxsis to access part of a multibillion dollar therapeutics market."


Dr Lorraine Martin, CEO of ProAxsis, said: "Our technology's competitive advantages include higher sensitivity and specificity in measuring active proteases in clinical samples than existing methods, which is resonating with customers. Receiving our first orders from two notable companies is a huge step forward for us and we expect a good conversion of our current pipeline."

ProAxsis is also developing a point-of-care (PoC) NEATstik™ test to measure active proteases in CF and COPD which will enable the proactive management of these diseases with the aim of improving patient outcome and reducing hospitalisations. NEATstik™ will enable entry into the rapidly growing PoC market that is estimated to be worth over £20 billion. The test has the potential to revolutionise the management of respiratory diseases, acting as an early monitoring device for patients to alert them of a potential infection.


-Ends-

Notes to Editors

ProAxsis
ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. The rapid and easy-to-use tests incorporate patented ProteaseTags™; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProAxsis also offers customers a highly experienced team that can provide clinical research services in regard to the specific measurement of active proteases within clinical samples as well as target validation.
ProAxsis was named one of Northern Ireland's most promising companies in 2013. It is also the only company in Northern Ireland, and one of only a few in the UK, to have secured a prestigious Horizon 2020 SME Instrument Award. For more information, please visit: www.proaxsis.com.

NetScientific
NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

For more information, please visit the website at www.netscientific.net.

[bumpa33] 22/7/2015 09:20

closed my short at 172 for 18 points, still sellers out there but Liberum do have a buyer in tow who's been picking up size at 180 and down.

[pennysharemillionaire2] 17/7/2015 12:17

I agree, the share price will drop back and sit around the previous resistance points until we get news on commerical deals, which won't come until Q4 (ish) according to timing.

[bumpa33] 17/7/2015 10:47

not with a seller around they won't, but folk seem to want to ignore that - i'd wager there's buyers at 150-160, i'd look for that level before taking the plunge.

[yasx] 17/7/2015 10:43

At the bottom of the range of the flag which followed the recent move from 130p - buying at these levels should lead to significant upside, with the hope of clearing the recent highs at marginally above 200p.

[bumpa33] 17/7/2015 07:32

funny then that Investec have a big seller into them right now? Also suspicious of that bloody Zak Mir and his bullish chart predictions because with experience they often seem to coincide with sellers of a stock - seen it all too many times before with his charts, enough to make me think it ain't coincidence...

[pennysharemillionaire2] 17/7/2015 07:28

so we agree then, only a matter of time ....

[pennysharemillionaire2] 16/7/2015 22:07

It won't go any higher until confirmation of commercial sales.

It will more likely drop back while we wait and cash is burned.

[themadstork] 16/7/2015 15:53

Looked like a transfer to me. Hopefully thresholds been crossed so we know who bought and who sold

[alphatrend1] 16/7/2015 15:38

Hopefully overhang is close to clearing with those large trades, if we start moving back up we will know!

[bumpa33] 16/7/2015 14:46

investec have a seller into them at the moment, hence the weakness.

[sharestobuy] 16/7/2015 14:25

I don't understand how we get great news and we say netscientic has 25% upside yet we fall. This really confuses me alot. What going on, fill me in

[pennysharemillionaire2] 16/7/2015 14:12

Can see it coming back down to 160p until we get confirmation on commercial sales near year end.

No fundamental reason for this, apart from impatient investors of course.

[themadstork] 15/7/2015 19:37

Disappointingly muted reaction today. Kudos to the board for listening and getting newsflow out there though; it is much appreciated.

[sharestobuy] 15/7/2015 19:33

13.5 x current share price. That's ridiculous. You'd be looking at around £25.00 a share??

[protean] 15/7/2015 07:54

Huge stored potential value from key assets according to Investec.

13.5x current share price.

[protean] 15/7/2015 07:47

Nice bit of news and hopefully just the start.

From the recent Investec note:

"Once newsflow on commercialisation, licencing deals or regulatory development occurs with key portfolio assets, we believe the share price looks set to re-rate materially."

[howdlep] 15/7/2015 07:46

Major shareholders

[howdlep] 15/7/2015 07:45

With Woodford holding such a large % and there being such a tiny free float, mm's are going to have to encourage sellers today. So watch this move very quickly today...

[hydrus] 15/7/2015 07:38

This one sounds much further developed than TEKs I have to say

[howdlep] 15/7/2015 07:35

Now lets see momentum build here, as we test and break the all time high of 210p...


free stock charts from uk.advfn.com